METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors

Nicolas André,Marie Cécile Le Deley,Clémence Léguillette,Alicia Probst, Leen Willems, Romain Travers,Isabelle Aerts,Cécile Faure-Conter, Gabriel Revond-Riviere,Victoria Min,Birgit Geoerger,Pascal Chastagner, Natascha Entz-Werlé,Pierre Leblond

European Journal of Cancer（2024）

引用 0|浏览9

暂无评分

摘要

•The safety of new metronomic regimen associated with nivolumab have been evaluated.•The combinations of metronomic regimens and nivolumab appear safe with no observed DLT.•Long term disease control has been observed in patients with high grade glioma and ATRT.•A randomized phase 2 trial is evaluating the addition of nivolumab to the metronomic regimen.

查看译文

关键词

Immunotherapy,Immune checkpoint inhibitors,Pediatric cancer,Metronomic chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要